Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open, Single Arm, Multicenter, Phase 2 Trial to Evaluate Efficacy and Safety of NB02 (Poseltinib) Combined with Rituximab and Lenalidomide As a Salvage Therapy for Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

NCT06737250 is registered in ClinicalTrials.gov with NOBO Medicine as lead sponsor.

NCT NCT06737250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06737250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open, Single Arm, Multicenter, Phase 2 Trial to Evaluate Efficacy and Safety of NB02 (Poseltinib) Combined with Rituximab and Lenalidomide As a Salvage Therapy for Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma
Lead sponsor
NOBO Medicine
Phase
Phase 2
Overall status
Recruiting
Start date
November 25, 2024
Completion date
December 31, 2027
Enrollment
33 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

primary cns lymphoma (pcnsl)